

Once-Weekly Lonapegsomatropin (TransCon hGH) Added to Once-Weekly Navepegritide (TransCon CNP) in Children with Achondroplasia: 26-Week Results from the Phase 2 COACH Trial

Ciara M McDonnell¹, Melita Irving², Line Aagaard Nolting³, Sohair G Abdelrahman⁴,
Lene Worsaae Dalby⁵, Jennifer M Iklé⁴, Simon Mejlhede Jensen⁵, Allison S Komirenko⁴,
Michael S Ominsky⁴, Aimee D Shu⁴, and Hanne B Hove³

¹Children's Health Ireland at Temple Street, Dublin, Ireland, ²Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, United Kingdom, ³Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁴Ascendis Pharma Inc, Palo Alto, CA, USA, ⁵Ascendis Pharma, Inc, Hellerup, Denmark



TransCon[®] technology

TransCon Carrier + Linker




Parent Drug



TransCon Prodrug

TransCon Carrier : Soluble; allows for systemic delivery



TransCon Linker : Specific for different parent drugs and release profiles (cleavage is dependent upon pH and temperature)



C-type natriuretic peptide (CNP)
Amino acid sequence identical to endogenous CNP (89-126)



Somatropin
human growth hormone (hGH)
Identical 191 amino acid sequence and size (22 kDa) as endogenous hGH

Navepegritide (TransCon CNP)

- Designed to provide continuous exposure to active CNP with once-weekly administration¹
- Under investigation for the treatment of achondroplasia


Lonapegsomatropin (TransCon hGH)

- Designed to provide sustained release of active, unmodified somatropin with once-weekly administration^{2,3}
- Approved for treatment of GH deficiency in children and adults^{4,5}

CNP, C-type natriuretic peptide; hGH, human growth hormone


¹Breinholt VM, et al. *J Pharmacol Exp Ther* 2019. ²Sprogø K, et al. *Endocr Connect* 2017. ³Thornton PS, et al. *J Clin Endocrinol Metab* 2021. ⁴SKYTROFA[™] (lonapegsomatropin-tcgd). Ascendis Pharma; 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf; Accessed: 29Aug2025. ⁵Ascendis Pharma (2022) SKYTROFA (previously lonapegsomatropin Ascendis Pharma) SmPC. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa>; Accessed: 29Aug2025.

CNP counteracts pathologic FGFR3 signaling in achondroplasia




CNP, C-type natriuretic peptide; FGF, fibroblast growth factor; FGFR3, fibroblast growth factor receptor 3; NPR-B, natriuretic peptide receptor B.
Adapted from Laederich MB & Horton WA. *Current Opin Pediatrics* 2010;22:516-523

Background: Navepegritide demonstrated superiority in AGV at Week 52 vs. placebo in the pivotal trial



The ANCOVA included treatment, stratification factor, baseline age, and baseline ACH-specific height Z-score as covariates. Box and whisker plot derived using observed data at Week 52. Each plot displays the 75th and 25th percentile (box edges), interquartile range (IQR; colored area), median (midline), and minimum and maximum observed values (whiskers) for each treatment arm.

GH and CNP have complementary actions at the growth plate, unlocking the potential for augmented growth in achondroplasia




CNP, C-type natriuretic peptide; FGFR3, fibroblast growth factor receptor 3; GH, growth hormone; IGF-1, insulin-like growth factor-1

¹Blum WF, et al. *Endocr Connect.* 2018. ²Devesa J, et al. *Clin Med Insights Endocrinol Diabetes* 2016. ³Rintz E, et al. *Int J Mol Sci* 2022. ⁴Krejci P, et al. *PLoS One* 2008. ⁵Horton WA, et al. *Lancet.* 2007. ⁶Miyazawa T, et al. *Endocrinology* 2002. ⁷Yasoda A, et al. *Nature Medicine* 2004. Figure adapted from Šromová, V, et al. *Cells* 2023.

Phase 2 COACH trial

Lonapegsomatropin added to navepegritide treatment in children with achondroplasia



Primary Efficacy Endpoint: Annualized growth velocity (AGV) at Week 52

Secondary Endpoints include: Change from baseline in height Z-score
Upper-to-lower body segment ratio (body proportionality)

Safety Endpoint: Treatment-emergent AEs, including injection site reactions (ISRs)

Biomarker Endpoint: IGF-1 SDS

AE, adverse event; IGF-1, insulin-like growth factor-1; SDS, standard deviation score

^a navepegritide (100 µg CNP/kg/week) and lonapegsomatropin (starting dose of 0.30 mg hGH/kg/week) administered as separate once-weekly subcutaneous injections

Demographics and baseline characteristics

- Mean baseline ACH-specific height Z-score in navepegritide-experienced group reflects prior navepegritide-driven growth

	navepegritide & lonapegsomatropin	
Full Analysis Set	Treatment-naïve (N=12)	Navepegritide-experienced (N=9)
Age, years; mean (SD)	4.7 (2.4)	7.9 (1.8)
Sex, male; n (%)	8 (66.7)	6 (66.7)
Prior exposure to navepegritide 100 µg CNP/kg/wk, years; mean (range)	Not Applicable	2.6 (2.3, 2.9)
AGV (cm/year); mean (SD)	4.92 (2.18)	5.14 (0.53)
ACH-specific height Z-score; mean (SD)^a	0.46 (0.70)	1.28 (0.81)
CDC-based height Z-score; mean (SD)^b	-4.46 (0.77)	-4.04 (0.66)
IGF-1 SDS; mean (SD)	-0.63 (1.32)	-0.70 (0.48)

n = number of participants with observation

ACH, achondroplasia; AGV, annualized growth velocity; CDC, Centers for Disease Control and Prevention; IGF-1, insulin-like growth factor-1; SD, standard deviation; SDS, standard deviation score


^aHoover-Fong JE, et al. US. *Orphanet J Rare Dis*. 2021.

^bCDC growth charts by age and sex available at: <https://www.cdc.gov/growthcharts/who-growth-charts.htm>

| Intended for education and scientific exchange only. Not for use in promotion or product commercialization.

Navepegritide & lonapegsomatropin resulted in significant improvement from baseline in AGV at Week 26

Annualized growth velocity (AGV)




Note: Gray arrow indicates change from baseline. Baseline AGV calculation is based on 6 months and 12 months preceding the COACH trial for treatment-naïve children and navepegritide-experienced children, respectively.

| Intended for education and scientific exchange only. Not for use in promotion or product commercialization.

Navepegritide & lonapegsomatropin resulted in significant improvement in ACH-specific height Z-score at Week 26

ACH-specific height Z-score



ACH, achondroplasia

Note: Gray arrow indicates change from baseline

AGV with navepegritide & lonapegsomatropin exceeded the 97th percentile for children of average stature






Figure adapted from Hoover-Fong JE, et al. *Am J Clin Nutr* 2008. Natural history AGV curves presented for male children; curves for average stature children from 0-3y reflect 10th, 50th, and 90th percentile; curves for average stature children >3y reflect percentiles as labeled.

| Intended for education and scientific exchange only. Not for use in promotion or product commercialization.

Children treated with navepegritide & lonapegsomatropin demonstrated improvement in body proportionality



Average IGF-1 SDS was maintained near protocol-specified threshold of +2.5



IGF-1, insulin-like growth factor-1; SDS, standard deviation score
Weekly average IGF-1 SDS was estimated using Lin et al, *J Endocr Soc* 2021. Plot represents median/IQR/range.

| Intended for education and scientific exchange only. Not for use in promotion or product commercialization.

Safety profile of navepegritide & lonapegsomatropin was consistent with safety profile of each monotherapy

Safety Analysis Set	COACH Overall (N=21) n (%)
Treatment-emergent AEs	15 (71.4)
AEs affecting ≥5% of children	
Injection site erythema	5 (23.8)
Nasopharyngitis	5 (23.8)
Viral gastroenteritis	2 (9.5)
Gastroenteritis	2 (9.5)
Lower respiratory tract infection	2 (9.5)
Hand-foot-and-mouth disease	2 (9.5)
Injection site bruising	2 (9.5)
Pyrexia	2 (9.5)
Arthralgia	2 (9.5)
Treatment-related AEs	7 (33.3)
Lonapegsomatropin-related AE	6 (28.6) ^a
Navepegritide-related AE	4 (19.0) ^b
AEs of special interest (for navepegritide)^c	
Injection site reactions	3 (14.3)
Symptomatic hypotension	0
Fractures	0
Serious AEs	1 (4.8) ^d
Change in bone age, mean (SE)	0.41 (0.11)

No AEs led to discontinuation of either study drug, withdrawal from trial, or death

AE, adverse event; N, number of children enrolled; n, number of children with observation; SE, standard error

^a AE related to lonapegsomatropin: injection site erythema (n=2); injection site discoloration (n= 1); injection site pain (n= 1); injection site swelling (n= 1); head circumference abnormal (n= 1); lipatrophy (n= 1)

^b AE related to navepegritide: injection site erythema (3); injection site bruising (n= 1); hypertrichosis (n= 1)

^c Defined for navepegritide per FDA; no AEs of special interest have been defined for lonapegsomatropin.

^d Viral respiratory tract infection, assessed as moderate and not related to either study drug by the investigator.

| Intended for education and scientific exchange only. Not for use in promotion or product commercialization.

Summary

- COACH is the first clinical trial to evaluate combination treatment with once-weekly navepegritide and once-weekly lonapegsomatropin in children with achondroplasia
- At Week 26, children receiving navepegritide and lonapegsomatropin demonstrated notable improvements in growth and body proportionality compared with baseline
- Combination treatment with navepegritide and lonapegsomatropin was well tolerated, with generally mild treatment-emergent adverse events

These results suggest co-administration of lonapegsomatropin with navepegritide results in augmented growth, with a safety profile consistent with the monotherapies

52-week results from the COACH trial are expected in early 2026

The authors and Ascendis Pharma thank the children, caregivers, study sites, and investigators who participated in this clinical trial.

Disclosures, acknowledgments, and funding

- Ciara M McDonnell: Research support/clinical trial investigator and consultant for Ascendis Pharma; consultant for BioMarin.
- Ascendis Pharma Growth Disorders A/S funded this trial and participated in the trial design, research, analysis, data collection, interpretation of the data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by MaryEllen Carlile Klusacek, PhD.
- Financial arrangements of the authors with companies whose products may be related to this presentation are listed as declared by the authors: **MI and HBH**: Research support/clinical trial investigator and consultant for Ascendis Pharma; **LAN**: Research support/clinical trial investigator for Ascendis Pharma; **SGA, LWD, JMI, SMJ, ASK, MSO** and **ADS** are employees of Ascendis Pharma, Inc.